Parenteral Artesunate Will Save ~ 200,000 Children with Severe Malaria Annually / Lao Medical Journal

ABSTRACT

Severe P. falciparum malaria kills people, particularly African children ~ 200,000 per year. Quinine and quinidine infusions were the only antimalarial drugs available to treat severe malaria until recently. The rediscovery of artemisinins in 1972 and subsequent synthesis of artemether and artesunate have provided highly effective alternatives to quinine. Results from meta¬analysis demonstrated that artemether significantly reduced mortality in adult patients with severe malaria from Southeast Asia. Pharmacokinetic studies suggest that the oil¬soluble artemether, which can be given intramuscularly but not intravenously, is poorly and slowly absorbed from the injection site while the water¬soluble artesunate is absorbed rapidly and reliably. The SEAQUAMAT study comparing intravenous artesunate vs quinine among adults and children in 4 Asian countries and demonstrated a significant absolute reduction of mortality of 34.7% (95%CI = 18.5 – 47.6%). A subsequent study (AQUAMAT study) conducted in African children with severe malaria in 9 countries confirmed the excellent efficacy of artesunate with a significant relative reduction of death of 22.5% (95%CI = 8.1 – 36.9%). A large meta¬analysis with more than 7,000 patients also confirmed that artesunate significantly reduced mortality in Africa of 22.5% and that in Asia of 38.6%. Patients treated with quinine had significantly higher incidence of hypoglycemia when compared to those who received artesunate. If these studies had been conducted 20 years earlier, perhaps 4 million patients with severe malaria would not have died particularly African children. Parenteral artesunate should replace quinine everywhere in the world as the first line treatment of severe falciparum malaria. Such a change in policy would save an estimated 200,000 live of children with severe malaria each year. With support from the Global Fund for the fight against AIDS, Tuberculosis and Malaria (GFATM), Laos changed the national policy of severe malaria treatment to artesunate as first line in 2006.